To those posting for the UC positions, ever heard of Krystexxa?

Quote

Anonymous

Guest
The UC drug will be the equivalent in the UC market as Krystexxa was to the gout market.




Savient Pharmaceuticals Files for Bankruptcy
By Karen Gullo - Oct 15, 2013 12:40 PM CT

Savient Pharmaceuticals Inc. (SVNT), the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC unit for $55 million, the company said.
Savient had $260 million in debt and $74 million in assets, according to a filing today in bankruptcy court in Wilmington, Delaware. An agreement with Sloan Holdings CV, a unit of Louisville, Kentucky-based US WorldMeds, calls for Sloan to acquire most of Savient, including the gout drug Krystexxa, for $55 million under a court-supervised auction process, Savient said in a statement.
The Sloan offer sets the floor for the auction, Bridgewater, New Jersey-based Savient said. The company’s largest shareholder is Palo Alto Investors LLC, which owns 15 percent of Savient common stock, followed by Franklin Templeton, with 8 percent, and Wellington Management Co. with 7 percent, according to a court filing.
Holders of $145 million of notes are Savient’s largest unsecured creditor, according to the filing.
As many as 6 million people in the U.S. suffer from gout, a type of arthritis in which deposits of uric acid build up around joints, causing pain, swelling and stiffness, according to the National Institutes of Health.
The case is In Re Savient Pharmaceuticals, 13-12680, U.S. Bankruptcy Court, District of Delaware (Wilmington).
To contact the reporter on this story: Karen Gullo in San Francisco at kgullo@bloomberg.net
 




Big differnce, Takeda has deep pockets. All those years Prevacid and Actos literally racked up 10's of BILLIONS of dollars. We aren't a tiny little biotech and can sustain whether or not this product is a success. Because we have the money, we will support this product like it needs be and turn it into a success.
 




Anonymous said:
The UC drug will be the equivalent in the UC market as Krystexxa was to the gout market.




Savient Pharmaceuticals Files for Bankruptcy
By Karen Gullo - Oct 15, 2013 12:40 PM CT

Savient Pharmaceuticals Inc. (SVNT), the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC unit for $55 million, the company said.
Savient had $260 million in debt and $74 million in assets, according to a filing today in bankruptcy court in Wilmington, Delaware. An agreement with Sloan Holdings CV, a unit of Louisville, Kentucky-based US WorldMeds, calls for Sloan to acquire most of Savient, including the gout drug Krystexxa, for $55 million under a court-supervised auction process, Savient said in a statement.
The Sloan offer sets the floor for the auction, Bridgewater, New Jersey-based Savient said. The company’s largest shareholder is Palo Alto Investors LLC, which owns 15 percent of Savient common stock, followed by Franklin Templeton, with 8 percent, and Wellington Management Co. with 7 percent, according to a court filing.
Holders of $145 million of notes are Savient’s largest unsecured creditor, according to the filing.
As many as 6 million people in the U.S. suffer from gout, a type of arthritis in which deposits of uric acid build up around joints, causing pain, swelling and stiffness, according to the National Institutes of Health.
The case is In Re Savient Pharmaceuticals, 13-12680, U.S. Bankruptcy Court, District of Delaware (Wilmington).
To contact the reporter on this story: Karen Gullo in San Francisco at kgullo@bloomberg.net
Click to expand...

what is your point? Both are infusion, so they are doomed? Please tell me why you think it should be anything like the Savient situation.
 




Anonymous said:
Big differnce, Takeda has deep pockets. All those years Prevacid and Actos literally racked up 10's of BILLIONS of dollars. We aren't a tiny little biotech and can sustain whether or not this product is a success. Because we have the money, we will support this product like it needs be and turn it into a success.
Click to expand...

Yeah yeah yeah just like Edarbi
 




















Anonymous said:
Big differnce, Takeda has deep pockets. All those years Prevacid and Actos literally racked up 10's of BILLIONS of dollars. We aren't a tiny little biotech and can sustain whether or not this product is a success. Because we have the money, we will support this product like it needs be and turn it into a success.
Click to expand...

Takeda HAD deep pockets. The company is running out of cash and has been pulling assets out of the U.S. for the last four years now.
 




Anonymous said:
what is your point? Please tell me why you think it should be anything like edarbi?
Click to expand...

Because the dolts in management at Takeda think that they can just throw money at a product and it will be successful. Example: Rozerem, Edarbi, Kapodex ;).....etc. this product will be the next in line, that's his point.

Too many people in management think they know what they are doing because they were lucky enough to be a sales rep when "the drugs that sell themselves" were generating profits. They never sold Actos or Prevacid.....those drugs sold THEM!
 
















Anonymous said:
The UC drug will be the equivalent in the UC market as Krystexxa was to the gout market.




Savient Pharmaceuticals Files for Bankruptcy
By Karen Gullo - Oct 15, 2013 12:40 PM CT

Savient Pharmaceuticals Inc. (SVNT), the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC unit for $55 million, the company said.
Savient had $260 million in debt and $74 million in assets, according to a filing today in bankruptcy court in Wilmington, Delaware. An agreement with Sloan Holdings CV, a unit of Louisville, Kentucky-based US WorldMeds, calls for Sloan to acquire most of Savient, including the gout drug Krystexxa, for $55 million under a court-supervised auction process, Savient said in a statement.
The Sloan offer sets the floor for the auction, Bridgewater, New Jersey-based Savient said. The company’s largest shareholder is Palo Alto Investors LLC, which owns 15 percent of Savient common stock, followed by Franklin Templeton, with 8 percent, and Wellington Management Co. with 7 percent, according to a court filing.
Holders of $145 million of notes are Savient’s largest unsecured creditor, according to the filing.
As many as 6 million people in the U.S. suffer from gout, a type of arthritis in which deposits of uric acid build up around joints, causing pain, swelling and stiffness, according to the National Institutes of Health.
The case is In Re Savient Pharmaceuticals, 13-12680, U.S. Bankruptcy Court, District of Delaware (Wilmington).
To contact the reporter on this story: Karen Gullo in San Francisco at kgullo@bloomberg.net
Click to expand...

Tru dat!
 












Anonymous said:
Because the dolts in management at Takeda think that they can just throw money at a product and it will be successful. Example: Rozerem, Edarbi, Kapodex ;).....etc. this product will be the next in line, that's his point.

Too many people in management think they know what they are doing because they were lucky enough to be a sales rep when "the drugs that sell themselves" were generating profits. They never sold Actos or Prevacid.....those drugs sold THEM!
Click to expand...

Truer words were never spoken
 




Top Bottom
Back
Quote